PNNL

Dr. Douglas Mans is the Director of PNNL’s Environmental Molecular Sciences Division and the Environmental Molecular Sciences Laboratory (EMSL) user program. EMSL is a national scientific user facility sponsored by the U.S. Department of Energy's (DOE) Biological and Environmental Research (BER) program. Overseeing the EMSL user program, Mans is the primary interface with DOE BER and PNNL leadership. He works closely with the user community for science, management, and operations of EMSL. His scientific vision attracts outstanding staff scientists and users to EMSL facilities and programs, promotes innovative research, and fosters the creation of robust scientific teams and communities. He leads more than 160 staff members in growing EMSL's reputation as a premier scientific user facility. 

A biopharmaceutical strategic science and technology expert, Mans has more than 13 years of experience in the pharmaceutical industry. Before joining PNNL and EMSL in 2019, he was Innovation Director at Janssen Pharmaceuticals, managing a portfolio of global external innovation projects and collaborations starting in 2017. Mans spent most of his career at GlaxoSmithKline (GSK), a multinational pharmaceutical company. He started in 2006 as an investigator/principal scientist. He held several management positions of increasing responsibility at GSK, including Innovation Seeker, Global Director of Continuous Processing, Asset Management Lead, and Global Director for Chemical Catalysis and Novel Methods. In 2016, he was part of a team at ViiV Healthcare, a GSK subsidiary, developing innovative solutions to challenges associated with HIV treatments and patient support. 

Previous Research Interests 

• Total synthesis of natural and pharmaceutically active compounds 
• Accessing novel heterocyclic compounds via [3+2] azaallyl anion cycloadditions 
• Strategic and organizational constructs to foster integrative approaches to challenging problems and opportunities in the energy, environmental, and human health sectors

• Postdoctoral Fellow, National Institutes of Health, The University of Texas, 2006 
• PhD in Synthetic Organic Chemistry, University of Michigan, 2004 
• BA in Chemistry, St. Louis University, 1999 (summa cum laude) 

• American Chemical Society

• Received two GSK Exceptional Science Awards for technical expertise
• Received two GSK Silver Impact Awards for creative contributions
• Receive three GSK Bronze Impact Awards for creative contributions

• Goodman SN, MD Kowalski, DM Mans, W Huan. “Processes for preparing pyridinone carboxylic acid aldehydes.” US Patent 8,889,877. 
• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing carbamoylpyridone derivatives and intermediates.” US Patent App. 16/207,288. 
• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing pyridinone carboxylic acid derivatives and intermediates.” US Patent App. 16/207,243. 
• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing carbamoylpyridone derivatives and intermediates.” US Patent App. 16/207,273. 
• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing carbamoylpyridone derivatives and intermediates.” US Patent App. 15/907,683. 
• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing carbamoylpyridone derivatives and intermediates.” US Patent App. 15/907,626. 
• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing (4R, 12aS)-N-(2, 4-difluorobenzyl)-7-hydroxy-4-methyl-6, 8-dioxo-3, 4, 6, 8, 12, 12a-hexahydro-2H-pyrido [1', 2': 4, 5] pyrazino [2, 1-b][1, 3] oxazine.” US Patent 9,938,296. 
• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing (4R, 12aS)-N-(2, 4-difluorobenzyl)-7-methoxy-4-methyl-6, 8-dioxo-3, 4, 6, 8, 12, 12A-hexahydro-2H-pyrido [1', 2': 4, 5] pyrazino [2, 1-b][1, 3] oxazine. US Patent 9,643,981. 
• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing (4R, 12aS)-7-methoxy-4-methyl-6, 8-dioxo-3, 4, 6, 8, 12, 12a-hexahydro-2H-pyrido [1', 2': 4, 5] pyrazino [2, 1-b][1, 3] oxazine-9-carboxylic acid.” US Patent 9,120,817. 
• Sisko J, D Mans, H Yin. “Process for preparing pyrano-[2, 3-C] pyridine derivatives.” US Patent 8,759,523. 

2024

• Eloe-Fadrosh E., P. Chain, S. Cholia, K. Fagnan, D.M. Mans, L. McCue, and C.J. Mungall, et al. 2024. DOE BSSD Performance Management Metrics Report Q3. PNNL-36162. Richland, WA: Pacific Northwest National Laboratory. DOE BSSD Performance Management Metrics Report Q3

2023

• Bowman M.M., A.E. Heath, T. Varga, A. Battu, R.K. Chu, J.G. Toyoda, and T. Cheeke, et al. 2023. "One thousand soils for molecular understanding of belowground carbon cycling." Frontiers in Soil Science 3. PNNL-SA-183617. doi:10.3389/fsoil.2023.1120425

2022

• Eloe-Fadrosh E., F. Ahmed, F. Anubhav, M. Babinski, J. Baumes, M.I. Borkum, and L.M. Bramer, et al. 2022. "The National Microbiome Data Collaborative Data Portal: an integrated multi-omics microbiome data resource." Nucleic Acids Research 50, no. D1:D828-D836. PNNL-SA-165796. doi:10.1093/nar/gkab990

Selected Publications

2018

• Egbert J.D., J.A. Lopez-Ruiz, S. Prodinger, J.D. Holladay, D.M. Mans, C.E. Wade, and R.S. Weber. 2018. "Counting surface redox sites in carbon-supported electrocatalysts by cathodic stripping of O deposited from N₂O." Journal of Catalysis 365, 405-410. doi: 10.1016/j.jcat.2018.07.026

2015

• Knueppel D., J. Yang, B. Cheng, D. Mans, and S.F. Martin. 2015. "Total synthesis of the aglycone of IB-00208." Tetrahedron 71 (35), 5741-5757. doi: 10.1016/j.tet.2015.05.024
• Yang J., D. Knueppel, B. Cheng, D. Mans, and S.F. Martin. 2015. "Approaches to polycyclic 1, 4-dioxygenated xanthones. Application to total synthesis of the aglycone of IB-00208." Organic Letters 17 (1), 114-117. doi:10.1021/ol503336t

2012

• Goodman S.N., D.M. Mans, J. Sisko, and H. Yin. 2012. "Synthesis of Fused Dihydropyrano(furano) pyridines via [4+ 2]-Cycloaddition of 5-Alkenoxy Substituted Oxazoles." Organic Letters 14 (6), 1604-1607. doi:10.1021/ol300351v

2011

• Calad S., D. Mans, J.A. Morin, S. O'Neill-Slawecki, and J. Sisko. 2011. "An expedient synthesis of cis/trans-1, 3-disubstituted cyclobutanols." Tetrahedron Letters 52 (32), 4207-4210. doi: 10.1016/j.tetlet.2011.06.027
• O'Keefe B.M., D.M. Mans, D.E. Kaelin Jr, and S.F. Martin. 2011. "Studies toward the syntheses of pluramycin natural products. The first total synthesis of isokidamycin." Tetrahedron 67 (35), 6524-6538. doi: 10.1016/j.tet.2011.05.117

2010

• O'Keefe B.M., D.M. Mans, D.E. Kaelin Jr, and S.F. Martin. 2010. "Total synthesis of isokidamycin." Journal of the American Chemical Society 132 (44), 15528-15530. doi:10.1021/ja107926f

2004

• Mans D.M. and W.H. Pearson. 2004. "Novel Kumada coupling reaction to access cyclic (2-azaallyl) stannanes. Cycloadditions of cyclic nonstabilized 2-azaallyllithium species derived from cyclic (2-azaallyl) stannanes." The Journal of Organic Chemistry 69 (19), 6419-6426. doi:10.1021/jo049429p
• Mans D.M., and W.H, Pearson. 2004. "Total Synthesis of (+)-Cocaine via Desymmetrization of a meso-Dialdehyde." Organic Letters 6 (19), 3305-3308. doi:10.1021/ol048777a
• Pearson W.H., D.M. Mans, and J.W. Kampf. 2004. "Cycloadditions of 2-azaallyllithium species with conjugated polyenes." The Journal of Organic Chemistry 69 (4), 1235-1247. doi:10.1021/jo030306z

2003

• Nicaise O.J.C., Mans D.M., Morrow A.D., Hefti E.V., Palkovacs E.M., Singh R.K., Zukowska M.A., and Morin M.D. 2003. "Stable enols from Grignard addition to 1, 2-diesters: serendipity rules." Tetrahedron 59 (34), 6433-6443. doi:10.1016/s0040-4020(03)01065-2

2002

• Pearson W.H., D.M. Mans, and J.W. Kampf. 2002. "Cycloadditions of Nonstabilized 2-Azaallyllithiums with Cycloheptatriene." Organic Letters 4 (18), 3099-3102. doi:10.1021/ol026423i